Genelux Corp GNLX
We take great care to ensure that the data presented and summarized in this overview for GENELUX CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in GNLX
Top Purchases
Top Sells
About GNLX
Insider Transactions at GNLX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 18
2024
|
Lourie S. Zak Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
41,650
+33.56%
|
-
|
|
Dec 18
2024
|
Joseph Cappello VP, Pharmaceutical Development |
BUY
Grant, award, or other acquisition
|
Direct |
29,000
+39.92%
|
-
|
|
Dec 18
2024
|
Tony Yu VP, Clinical Trial Operations |
BUY
Grant, award, or other acquisition
|
Direct |
29,000
+42.11%
|
-
|
|
Dec 18
2024
|
Sean Ryder General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
22,000
+34.71%
|
-
|
|
Dec 18
2024
|
Ralph Smalling Head of Regulatory |
BUY
Grant, award, or other acquisition
|
Direct |
15,525
+32.77%
|
-
|
|
Dec 18
2024
|
Thomas Zindrick President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
134,500
+43.9%
|
-
|
|
Dec 16
2024
|
Joseph Cappello VP, Pharmaceutical Development |
SELL
Open market or private sale
|
Direct |
6,300
-30.07%
|
$12,600
$2.34 P/Share
|
|
Dec 16
2024
|
Ralph Smalling Head of Regulatory |
SELL
Open market or private sale
|
Direct |
2,510
-13.33%
|
$5,020
$2.34 P/Share
|
|
Dec 16
2024
|
Lourie S. Zak Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,103
-4.9%
|
$4,206
$2.34 P/Share
|
|
Dec 16
2024
|
Thomas Zindrick President and CEO |
SELL
Open market or private sale
|
Direct |
14,315
-27.7%
|
$28,630
$2.34 P/Share
|
|
Sep 13
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
33,080
-5.23%
|
$66,160
$2.57 P/Share
|
|
Sep 12
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
31,777
-4.78%
|
$63,554
$2.73 P/Share
|
|
Sep 11
2024
|
James L Tyree |
SELL
Open market or private sale
|
Direct |
1,730
-3.51%
|
$3,460
$2.6 P/Share
|
|
Sep 11
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
31,376
-4.51%
|
$62,752
$2.62 P/Share
|
|
Sep 10
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
20,384
-2.85%
|
$40,768
$2.51 P/Share
|
|
Sep 09
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
23,383
-3.16%
|
$46,766
$2.7 P/Share
|
|
Sep 03
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
42,818
-5.47%
|
$85,636
$2.09 P/Share
|
|
Aug 30
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
142,589
-15.41%
|
$285,178
$2.17 P/Share
|
|
Aug 29
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
107,045
-10.37%
|
$107,045
$1.98 P/Share
|
|
Aug 28
2024
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
15,918
-1.52%
|
$31,836
$2.05 P/Share
|
Last 12 Months Summary
Buy / Acquisition
788K
Shares
From
20
Insiders
| Grant, award, or other acquisition | 520K shares |
|---|---|
| Open market or private purchase | 268K shares |
Sell / Disposition
816K
Shares
From
9
Insiders
| Open market or private sale | 816K shares |
|---|